Junho Hur

Associate Professor

Hanyang University
Country flagSouth Korea

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (12)

Year:

2026

Neonatal neuroinflammation, driven by microglial activation and cytokine signaling, contributes to brain injury and adverse neurodevelopment outcomes. Perinatal inflammatory mediators, including interleukin-6, cyclooxygenase-2, and interleukin-17, prime microglia and influence circuit vulnerability. This study investigated whether oxytocin pretreatment attenuates lipopolysaccharide-induced inflammatory priming in BV-2 microglial cells. BV-2 microglia were preincubated with oxytocin (33 ng/mL) for 2 h, followed by lipopolysaccharide (0.5 µg/mL) for 2 h. Expression of ionized calcium-binding adapter molecule 1, a microglia marker, in BV-2 cells was assessed by immunofluorescence. After lipopolysaccharide treatment, the gene expression of BV-2 cells was assayed at 1, 2, and 6 h post stimulation by RT-qPCR and RNA-seq. Functional characterization of gene expression profile was performed. Analyses of gene expression profile of BV-2 cells by RT-qPCR and RNA-seq revealed that oxytocin pretreatment attenuated lipopolysaccharide-induced transcriptional activation, including interleukin-6 and cyclooxygenase-2 upregulation. Pathway enrichment analyses suggested that oxytocin-responsive genes were linked to the interleukin-17 signaling pathway. Gene Ontology enrichment analysis showed enrichment for genes related to cytokine production, membrane raft, and chemokine activity. Oxytocin pretreatment mitigates lipopolysaccharide-induced microglial activation by modulating the interleukin-17–interleukin-6/cyclooxygenase-2 axis, suggesting its potential role for oxytocin as an endogenous modulator of neuroinflammation during early brain development.

Year:

2026

Dysregulated insulin signaling reduces HNSCC tumor growth. A, Plasma insulin concentration of vehicle- or STZ-treated mice (40 mg/kg i.p. for 5 consecutive days; n = 4 for each group). Two-tailed t test. *, P B, Representative H&E staining of pancreatic tissues collected from vehicle- or STZ-treated mice. Dashed lines denote individual pancreatic islets. Scale bars, 1 mm. C, Intraperitoneal glucose tolerance test of vehicle- and STZ-treated mice ( n = 4 for each group). D, In vivo tumor growth of FaDu xenograft tumors in vehicle-treated ( n = 4) and STZ-treated ( n = 4) mice. Two-way ANOVA. ****, P E, H&E and IHC analyses of pH2A.X, 4HNE, and Ki67 in FaDu xenograft tumors collected from vehicle- and STZ-treated mice. Scale bars, 1 mm. F, IHC analysis quantification of % area of 4HNE (lipid peroxidation marker), pH2A.X (DNA damage marker), and Ki67 (nuclear/cell proliferation marker) in xenografted tumors. Four to six images of each tumor were captured and analyzed for quantification ( n = 4 for each group). Two-tailed t test, **, P P

Year:

2025

Auranofin induces cytotoxicity as a pro-oxidant in HNSCC. A and B, In vitro proliferation (top) and intracellular H 2 O 2 levels (bottom) of FaDu ( A ) or SCC-61 ( B ) cells treated with vehicle, WZB117 (20 μmol/L), auranofin (1 μmol/L), or combination of WZB117 and auranofin ( n = 6 for each group). Two-way ANOVA (top) or two-tailed t test (bottom). ****, P P P C–F, In vivo tumor growth ( C ), tumor weights ( D ), images of individual tumors ( E ), and IHC analysis of GLUT1, pH2A.X, 4HNE, and CC3 ( F ) in SCC-61 xenograft tumors treated with vehicle PBS/DMSO ( n = 6) or auranofin (10 mg/kg i.p. daily; n = 6). Two-way ANOVA for tumor growth ( C ) and two-tailed t test for tumor weight ( D ). ****, P P G, IHC analysis quantification of % area of 4HNE (lipid peroxidation marker), pH2A.X (DNA damage marker), and CC3 (apoptotic cell marker) in xenografted tumors ( n = 6 for each group). Four to six images of each tumor were captured and analyzed for quantification. Two-tailed t test. **, P H, In vivo tumor growth of FaDu xenograft tumors treated with vehicle PBS/DMSO ( n = 16), WZB117 (20 mg/kg i.p. daily; n = 16), auranofin (10 mg/kg i.p. daily; n = 15), or combination of WZB117 and auranofin ( n = 12). Two-way ANOVA. ****, P P P I, In vivo tumor growth of SCC-61 xenograft tumors treated with vehicle PBS/DMSO ( n = 6), WZB117 (20 mg/kg i.p. daily; n = 7), auranofin (10 mg/kg i.p. daily; n = 7), or combination of WZB117 and auranofin ( n = 7). Two-way ANOVA. ****, P P P

Year:

2025

GLUT1 ablation attenuates tumorigenesis in 4NQO-induced mouse model of human HNSCC. A, Schematic showing timeline for treatment of mice with 4NQO. 4NQO was administered in drinking water for 8 weeks and replaced with normal drinking water for the remainder of the study. Tongues were collected every 2 weeks after the first exposure to 4NQO for analyses. For Cre-mediated GLUT1 ablation in basal epithelial cells, tamoxifen was injected (100 mg/kg i.p. daily for 5 consecutive days) 4 weeks after the final administration of 4NQO. Tumors were harvested 4 weeks after the final tamoxifen injection. B, Representative IHC analyses of GLUT1 expression in CK5 + and p63 + basal epithelial cells of untreated and 4NQO-treated mice. C, Representative images of tumor-bearing tongues from 4NQO-treated mice; black arrowheads depict squamous tongue tumors (left). Graph shows quantification of the number of visible tongue tumors identified in 4NQO-treated WT and Krt5 + basal epithelial–specific GLUT1 CKO mice ( n = 6 for each group). Mann–Whitney U test. P = 0.06 (right). D, Representative H&E images of 4NQO-treated WT and CKO mouse tongues. Arrows depict 4NQO-induced squamous tumors (left). Graph shows quantification of 4NQO-induced tongue tumor area (μm 2 ) in GLUT1 WT and CKO mice ( n = 6 for each group). Mann–Whitney U test. **, P E, Representative co-immunofluorescent staining of GLUT1 and p63 in 4NQO-induced squamous tongue tumors of GLUT1 WT and GLUT1 CKO mice. DAPI, 4',6-diamidino-2-phenylindole. F, Representative IHC analyses of p63, GLUT1, and Ki67 expression in 4NQO-induced squamous tongue tumors. All error bars represent mean ± SEM. All scale bars, 1 mm unless otherwise noted. H&E, hematoxylin and eosin; KO, knockout.

Year:

2025

Head and neck squamous cell carcinoma (HNSCC) remains a clinically challenging malignancy with limited targeted therapy options and poor patient outcomes. Thus, identifying unique dependencies, including HNSCC-specific metabolic reprogramming, is imperative for improving treatment strategies for this disease. In this study, we show that HNSCC relies on elevated glucose transporter 1 (GLUT1)–mediated glucose uptake to support redox homeostasis and tumor growth. Analyses of GLUT1 expression data in tumors and cancer cell lines reveal significant upregulation of GLUT1 in HNSCC relative to both normal tissue and other cancer subtypes and that high GLUT1 expression correlates with poorer clinical outcomes. Using a basal epithelial layer–specific GLUT1-knockout mouse model, we demonstrate that GLUT1 ablation in HNSCC cells of origin markedly attenuates tumor initiation and progression, implicating the necessity of GLUT1 in HNSCC tumorigenesis. Building on this observation, combining pharmacologic inhibition of GLUT1 with pro-oxidants such as vitamin C and auranofin induces potent cytotoxicity in vitro and in vivo , partly by precipitating oxidative stress. We further observe that insulin signaling is required to sustain glucose uptake and redox homeostasis, as insulin receptor knockdown decreases proliferation and increases reactive oxygen species levels. Together, these results suggest that although GLUT1 overexpression is a key driver of glucose uptake, insulin signaling also contributes to the metabolic and oncogenic pathways underlying HNSCC progression. Consequently, strategies that co-target GLUT1 and insulin signaling to restrict glucose flux may synergize with pro-oxidant therapies, offering a promising therapeutic avenue for HNSCC. Significance: Enhanced GLUT1 expression and oncogenic insulin signaling drive elevated glucose uptake in HNSCC, which contribute to the maintenance of redox homeostasis and tumor growth. Disrupting both glucose uptake and redox balance may offer a promising therapeutic approach.

Year:

2025

Insulin signaling promotes glucose-mediated antioxidative capacities in HNSCC. A, In vitro proliferation of FaDu cells in 25 mmol/L glucose media treated with or without 5 ng/mL insulin ( n = 4 for each group). Two-way ANOVA. ****, P B, Immunoblot analysis of pAKT and total AKT expression in FaDu cells treated with 20 ng/mL insulin over a time period of 0–120 minutes. C and D, Relative glucose uptake ( C ) and intracellular ROS measurement ( D ) in FaDu cells treated with 20 ng/mL insulin in 25 or 5 mmol/L glucose conditions ( n = 3 for each group). Two-tailed t test. ****, P P P E, In vitro proliferation of shScr, shINSR, or shINSR + 5 mmol/L NAC FaDu cells ( n = 4 for each group). Two-way ANOVA. **, P F, Immunoblot analyses of shScr and shINSR FaDu cells. β-Actin was used as the loading control. G and H, Relative glucose uptake ( G ) and intracellular ROS levels ( H ) in shScr and shINSR FaDu cells ( n = 3). Two-tailed t test. ****, P P I and J, In vitro proliferation of shScr, oncogenic mutant AKT E17K and PIK3CA H1047L expressing FaDu cells grown in 5 or 25 mmol/L glucose media ( n = 4 for each group). Two-way ANOVA. ****, P K, Immunoblot analysis of pAKT, AKT, pS6, S6, p4EBP1, and 4EBP1 expression in shScr and mutant AKT E17K and PIK3CA H1047L FaDu cells. L, Relative cellular glucose uptake and intracellular H 2 O 2 levels in FaDu PIK3CA H1047L mutant cells cultured in 5 or 25 mmol/L glucose ( n = 3 for each group). Two-tailed t test. ***, P M, Relative cellular glucose uptake and intracellular H 2 O 2 levels in FaDu AKT E17K mutant cells cultured in 5 or 25 mmol/L glucose ( n = 3 for each group). Two-tailed t test. *, P

Year:

2025

Combination of GLUT1 inhibition and ascorbate suppresses HNSCC tumor growth. A and B, In vitro proliferation (top) and intracellular H 2 O 2 levels (bottom) of FaDu ( A ) or SCC-61 ( B ) cells treated with WZB117 (20 μmol/L) or BAY-876 (100 nmol/L) and vitamin C (0.25 mmol/L) or combination of GLUT1 inhibitor and vitamin C ( n = 5 for each group). Two-way ANOVA (top) or two-tailed t test (bottom). ****, P P P P C, In vivo tumor growth of FaDu xenografts treated with vehicle PBS/DMSO, WZB117 (20 mg/kg i.p. daily), or BAY-876 (4.5 mg/kg of corn oil/DMSO p.o. daily; n = 6 for each group). Two-way ANOVA. ****, P D, In vivo tumor growth of FaDu xenograft tumors treated with vehicle PBS/DMSO ( n = 16), WZB117 (20 mg/kg i.p. daily; n = 16), vitamin C (4 g/kg i.p. daily; n = 7), and a combination of WZB117 and vitamin C ( n = 7). Two-way ANOVA. ****, P P P E–G, In vivo tumor growth of SCC-61 xenografts ( E ), tumor weights ( F ), IHC analysis of 4HNE, Ki67, and pH2A.X ( G ) in SCC-61 xenograft tumors treated with vehicle PBS/DMSO ( n = 6), WZB117 (20 mg/kg i.p. daily; n = 5), vitamin C (4 g/kg i.p. daily; n = 5), or combination of WZB117 and vitamin C ( n = 6). Two-way ANOVA. **, P P H, IHC analysis quantification of % area of 4HNE (lipid peroxidation marker), pH2A.X (DNA damage marker), and Ki67 (nuclear/cell proliferation marker) in xenografted tumors. Four to six images of each tumor were captured and analyzed for quantification. Two-tailed t test. *, P

Year:

2025

GLUT1 inhibition enhances cytotoxic oxidative stress in human HNSCC cell lines. A, In vitro proliferation and immunoblot analyses of shScramble (shScr) and shRNA-mediated KD of GLUT1 (shGLUT1) in HNSCC cell line FaDu ( n = 4 for each group). Two-way ANOVA. ****, P B, Relative glucose uptake and ( C ) intracellular ROS measurement in shScr and shGLUT1 FaDu cells ( n = 3 for each group). Two-tailed t test. ***, P P D, In vitro proliferation of shScr, shGLUT1, and shGLUT1 + NAC (5 mmol/L) in HNSCC cell line SCC-61 ( n = 4 for each group). Two-way ANOVA. ****, P E, Intracellular ROS measurement of shScr, shGLUT1, and shGLUT1 + NAC (5 mmol/L) in SCC-61 cells ( n = 3 for each group). Two-tailed t test. ****, P P F and G, In vitro proliferation of FaDu cells treated with GLUT1 inhibitors, WZB117 (0–40 μmol/L) or BAY-876 (0–100 nmol/L; n = 3 for each group). H and I, In vitro proliferation of FaDu ( H ) or SCC-61 ( I ) treated with WZB117 (30 μmol/L) or BAY-876 (150 nmol/L) with or without 5 mmol/L NAC treatment ( n = 6 for each group). Two-way ANOVA. ****, P P P 2 O 2 measurement of FaDu ( H ) or SCC-61 ( I ) cells treated with WZB117 (30 μmol/L) or BAY-876 (150 nmol/L) with or without 5 mmol/L NAC treatment ( n = 6 for each group). Two-tailed t test. ****, P P P

Year:

2025

GLUT1 inhibition potentiates oxidative cytotoxicity of radiation in human HNSCC cell lines. A and B, In vitro proliferation (top) and intracellular H 2 O 2 levels (bottom) of FaDu cells treated with WZB117 (20 μmol/L; A ) or BAY-876 (100 nmol/L; B ) with or without radiotherapy (RT, 4 Gy; n = 6 for each group). Two-way ANOVA (top) or two-tailed t test (bottom). ****, P P C and D, In vitro proliferation (top) and intracellular H 2 O 2 levels (bottom) of SCC-61 cells treated with WZB117 (20 μmol/L; C ) or BAY-876 (100 nmol/L; D ) with or without radiation (RT, 4 Gy; n = 6 for each group). Two-way ANOVA (top) or two-tailed t test (bottom). ****, P P E–J, Colony formation of HNSCC cells FaDu ( E , F , and I ) and Detroit 562 ( G , H , and J ) treated with WZB117 (20 μmol/L) or BAY-876 (100 nmol/L) with or without RT (4 Gy). Colonies were stained with crystal violet, and the colony area was measured using ImageJ ( n = 3). Two-tailed t test. ****, P P P P

Year:

2025

Year:

2025

Year:

2024

Collaborators (12)

Tae Gyu Oh

Assistant Professor

University of Oklahoma Health Sciences Center

UNITED STATES
View details

Jung-whan Kim

Associate Professor

University of Oklahoma

UNITED STATES
View details

Pankaj Singh

Professor and Chair

University of Oklahoma Health Sciences Center

UNITED STATES
View details

Jaewoo Hong

Assistant Professor

Catholic University of Korea School of Medicine

SOUTH KOREA
View details

Chul‐Ho Kim

Ajou University

SOUTH KOREA
View details

Dinesh Thotala

Associate Professor

University of Oklahoma Health Sciences Center

UNITED STATES
View details

Hoon Hur

Professor

Ajou University

SOUTH KOREA
View details

Seong-Ho Park

Hanyang University

SOUTH KOREA
View details

Junseok W Hur

Associate Professor

Seoul National University Hospital

SOUTH KOREA
View details

Jiyoung Lee

George Washington University

UNITED STATES
View details

Tae Hoon Kim

Professor

University of Texas at Dallas

UNITED STATES
View details

Ji Yun Jeong

Sungkyunkwan University School of Medicine

SOUTH KOREA
View details